Huma Therapeutics Stock
Huma provides a digital health platform used for predictive care and research.
Sign up today and learn more about Huma Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Huma Therapeutics Stock
Huma is a global health technology company that provides a modular platform to support digital 'hospitals at home' across different disease areas. Its platform combines predictive algorithms, digital biomarkers, and real-world data to advance proactive, predictive care and research. The company was founded in 2011 and is headquartered in London, England.
Funding History
| March 2021 | $90.9M |
|---|
Management
Co-founder & CEO
Dan Vahdat
Co-founder and Executive Director
Rich Khatib
SVP Business Development, US
Paul Costello
Life Sciences Partnerships Manager
Emily Deacon
Product Design Lead
Nicholas O'Donnell-Hoare
Head of Healthcare
Jonathan Gledhill
Talent Partner - Technology and Product
Adam Jones
Board Member
Claudia Suessmuth-Dyckerhoff
Senior Vice President
Alex Senemar
Advisor
Shayan Zadeh
Board Member
Rt Hon Alan Milburn
Press
TechCrunch - Apr, 16 2020
Medopad rebrands as Huma, acquires BioBeats and TLT to expand its biomarker platformEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
